HORSHOLM, Denmark, Feb. 29, 2012 /PRNewswire/ -- Edward Koval, senior vice president, business development, of Veloxis Pharmaceuticals A/S, will present at the Cowen and Company 32nd Annual Health Care Conference at 2:10 p.m. EST, Monday, March 5, at the Boston Marriott Copley Place in Boston. Mr. Koval will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro, Veloxis' candidate to prevent organ transplant rejection.
About Veloxis Pharmaceuticals A/S
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development.
For further information, please visit www.veloxis.com.
For U.S. investor and media contacts:
John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
SOURCE Veloxis Pharmaceuticals A/S